Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Resected Stage Clear all
Active, not recruiting Phase 2 Interventional

Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

NCT03127774
View directory record Official record
Conditions
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
Interventions
Cisplatin, Sodium thiosulfate, Cytoreductive surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer

NCT02138214
View directory record Official record
Conditions
Stage I Papillary Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage III Papillary Thyroid Cancer
Interventions
Thyroidectomy, entral lymph node dissection (CLND), Quality-of-life assessment
Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 73 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

NCT00861406
View directory record Official record
Conditions
Melanoma
Interventions
Pegylated Interferon-Alfa 2b (PEG Intron), GP-100 Peptide Vaccine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 23, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

NCT02656706
View directory record Official record
Conditions
Melanoma
Interventions
Ipilumumab, Nivolumab
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

NCT00060333
View directory record Official record
Conditions
Recurrent Melanoma
Interventions
radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
39
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Joliet, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jul 23, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

NCT00971191
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery

NCT00011960
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, paclitaxel, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer

NCT00726622
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Open laparotomy and rectal resection, Laparoscopic-assisted rectal resection
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
35
States / cities
Scottsdale, Arizona • Concord, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and GM-CSF in Biliary Cancer

NCT02703714
View directory record Official record
Conditions
Biliary Cancer
Interventions
Pembrolizumab, Sargramostim
Drug
Lead sponsor
Robin Kate Kelley
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Jul 23, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional Results available

Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

NCT03122106
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions
Personalized neoantigen DNA vaccine, TDS-IM Electrode Array System, Peripheral blood draws
Biological · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

NCT01498289
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
Interventions
FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
508
States / cities
Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

NCT00096226
View directory record Official record
Conditions
Lung Cancer
Interventions
Induction Carboplatin, Induction Paclitaxel, Resection, Consolidation Carboplatin, Radiation Therapy, Consolidation Paclitaxel
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 23, 2026, 5:32 AM EDT
Withdrawn Not applicable Interventional

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

NCT02250378
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions
stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
Radiation · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Jul 23, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291
View directory record Official record
Conditions
Melanoma
Interventions
Fianlimab, Cemiplimab, Pembrolizumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Adjuvant Aflibercept for Metastatic Colorectal Cancer

NCT01669720
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Aflibercept
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 23, 2026, 5:32 AM EDT
Active, not recruiting Not applicable Interventional

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

NCT01817192
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Drug · Other
Lead sponsor
Razor Genomics
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jul 23, 2026, 5:32 AM EDT
Active, not recruiting Not applicable Interventional

A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases

NCT05341739
View directory record Official record
Conditions
Brain Metastases, Adult
Interventions
Pre-operative Stereotactic Radiosurgery
Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jul 23, 2026, 5:32 AM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients

NCT01450657
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics/Renadyl
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

NCT00692770
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Nexavar (Sorafenib, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 23, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Springdale, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 5:32 AM EDT
Terminated Phase 3 Interventional Results available

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

NCT04410445
View directory record Official record
Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
Interventions
Bempegaldesleukin, Nivolumab
Biological
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
62
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Jul 23, 2026, 5:32 AM EDT
Terminated Phase 3 Interventional

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

NCT00087256
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer

NCT00063960
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Little Rock, Arkansas • Lexington, Kentucky • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 23, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Phase 1a Study to Evaluate Immunogenicity of ASV®

NCT03673020
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
ASV® AGEN2017 + QS-21 Stimulon® adjuvant
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Jul 23, 2026, 5:32 AM EDT